Literature DB >> 19171407

Dose intensity correlate with survival in elderly patients treated with chemotherapy for advanced non-small cell lung cancer.

A Luciani1, C Bertuzzi, G Ascione, E Di Gennaro, S Bozzoni, S Zonato, D Ferrari, P Foa.   

Abstract

INTRODUCTION: In elderly patients treated with chemotherapy for advanced non-small cell lung cancer (NSCLC), frequently an adequate dose intensity (DI) is difficult to be delivered. We therefore performed in this population a study to assess the delivered DI and its impact on clinical outcome. PATIENTS AND METHODS: Inclusion criteria were: age equal or greater than 70 years; cytological or histological diagnosis of NSCLC; stage IIIB or IV; no previous chemotherapy for advanced disease. Total relative dose intensity (RDI) was taken into account for the analysis. An RDI less than 80% was considered as suboptimal for tumor shrinkage. A survival comparison between subgroups (more or less than 80% RDI) was done.
RESULTS: 107 patients were eligible for the analysis. Mean age was 74.3 years. PS was 0-1 in 92.5% of subjects. Mean number of comorbidities was 1.86. The most frequently chemotherapy regimens used were single agent vinorelbine and single agent gemcitabine. Overall mean RDI was 68%; 36% of patients received a RDI>80% of the originally planned one. The objective response rate (RR) was 55.2% and 33.3% respectively for patients receiving more or less than 80% of the RDI (p<0.01); a significant difference in overall survival between these two groups (p<0.0001) was also recorded. Baseline hemoglobin and body mass index (BMI) were the variables that significantly influenced the delivered RDI.
CONCLUSIONS: These data suggest that in elderly patients treated with chemotherapy for advanced NSCLC an adequate dose intensity has a significant positive impact on both response rate and overall survival.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19171407     DOI: 10.1016/j.lungcan.2008.12.019

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  10 in total

Review 1.  Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer.

Authors:  M A Socinski
Journal:  Curr Oncol       Date:  2014-10       Impact factor: 3.677

2.  Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies.

Authors:  David J Kuter
Journal:  Haematologica       Date:  2022-06-01       Impact factor: 11.047

3.  Neutropenia and relative dose intensity on adjuvant FOLFOX chemotherapy are not associated with survival for resected colon cancer.

Authors:  Martin Smoragiewicz; Khodadad R Javaheri; Yaling Yin; Sharlene Gill
Journal:  J Gastrointest Cancer       Date:  2014-12

4.  Predicting neutropenia risk in patients with cancer using electronic data.

Authors:  Pamala A Pawloski; Avis J Thomas; Sheryl Kane; Gabriela Vazquez-Benitez; Gary R Shapiro; Gary H Lyman
Journal:  J Am Med Inform Assoc       Date:  2017-04-01       Impact factor: 4.497

5.  Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial.

Authors:  Anne S Tsao; Suyu Liu; J Jack Lee; Christine Alden; George Blumenschein; Roy Herbst; Suzanne E Davis; Edward Kim; Scott Lippman; David Stewart; Xi Ming Tang; Ignacio Wistuba; Waun Ki Hong
Journal:  J Thorac Oncol       Date:  2012-11       Impact factor: 15.609

6.  Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials.

Authors:  Piera Gargiulo; Laura Arenare; Cesare Gridelli; Alessandro Morabito; Fortunato Ciardiello; Vittorio Gebbia; Paolo Maione; Alessia Spagnuolo; Giuliano Palumbo; Giovanna Esposito; Carminia Maria Della Corte; Floriana Morgillo; Gianfranco Mancuso; Raimondo Di Liello; Adriano Gravina; Clorinda Schettino; Massimo Di Maio; Ciro Gallo; Francesco Perrone; Maria Carmela Piccirillo
Journal:  BMC Cancer       Date:  2021-05-14       Impact factor: 4.430

Review 7.  [The status and prospects of treatment protocols for elderly patients with non-small cell lung cancer].

Authors:  Jianping Zhou; Beili Gao
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2011-07

8.  Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer.

Authors:  Jeffrey Crawford; Neelima Denduluri; Debra Patt; Xiaolong Jiao; Phuong Khanh Morrow; Jacob Garcia; Richard Barron; Gary H Lyman
Journal:  Support Care Cancer       Date:  2019-06-07       Impact factor: 3.603

9.  Chemotherapy-induced neutropenia as a prognostic factor in advanced non-small-cell lung cancer: results from Japan Multinational Trial Organization LC00-03.

Authors:  Y Kishida; M Kawahara; S Teramukai; K Kubota; K Komuta; K Minato; T Mio; Y Fujita; T Yonei; K Nakano; M Tsuboi; K Shibata; S Atagi; T Kawaguchi; K Furuse; M Fukushima
Journal:  Br J Cancer       Date:  2009-09-29       Impact factor: 7.640

10.  A phase II study of FOLFIRINOX with primary prophylactic pegfilgrastim for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer.

Authors:  Mitsuhito Sasaki; Hideki Ueno; Shuichi Mitsunaga; Akihiro Ohba; Hiroko Hosoi; Satoshi Kobayashi; Makoto Ueno; Tetsuji Terazawa; Masahiro Goto; Dai Inoue; Shin Namiki; Yasunari Sakamoto; Shunsuke Kondo; Chigusa Morizane; Masafumi Ikeda; Takuji Okusaka
Journal:  Int J Clin Oncol       Date:  2021-08-08       Impact factor: 3.402

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.